Core Viewpoint - The company announced a licensing and collaboration agreement with Windward Bio Group AG's subsidiary, LE2025 Therapeutics AG, granting exclusive rights to develop and commercialize QX027N in specified regions outside of mainland China and certain special administrative regions [1] Group 1: Agreement Details - The agreement allows LE2025 to develop and commercialize QX027N globally, excluding mainland China, Taiwan, Hong Kong, and Macau [1] - The company or its designated subsidiaries are entitled to receive up to $700 million in total payments, which include an upfront payment, equity from Windward Bio, development and commercial milestone payments, and tiered royalties based on net sales of QX027N in the licensed regions [1] Group 2: Product Information - QX027N is a long-acting bispecific antibody targeting TSLP and IL-13, developed in-house by the company [1]
荃信生物-B(02509.HK)与Windward Bio附属公司就QX027N的开发及商业化签订许可及合作协议